Review of agents in late-stage development for the treatment of ankylosing spondylitis, osteoarthritis, and related pain (December 2006).
FDA Sets Review Date for Chronic Lung Disease Therapy
Regulators have set a goal of Aug. 12, 2025, for brensocatib to treat patients with non-cystic fibrosis bronchiectasis, a chronic lung disease.
Read More
FDA Approves Susvimo for Diabetic Macular Edema
Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a refillable ocular implant.
FDA Approves Third Biosimilar of Actemra
The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.
Evernorth Drives Cigna's Strong Revenue Growth and Focuses on Biosimilars and Drug Affordability
FDA Approves Ozempic to Reduce Kidney Disease in Type 2 Diabetes
Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common complication of type 2 diabetes.
FDA Approves New IV Maintenance Dose of Leqembi
A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research shows.